抗VEGF治療を強化するBARD1の表遺伝子調節
Emine Bayraktar1, Cristian Rodriguez-Aguayo2, Elaine Stur3
1Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Houston, Houston, TX 77030, USA.
Cell reports. Medicine
|September 4, 2025
まとめ
科学者は,BARD1タンパク質のレベルを回復することで,抗VEGF治療に対する抵抗を克服することができると発見しました. 癌治療の有効性を高める 新しい戦略を提示します
科学分野:
- 腫瘍学
- 分子生物学
- エピジェネティクス
- がん治療に対する耐性
背景:
- 血管内皮成長因子抗体 (AVA) は臨床的に使用されていますが,しばしば治療抵抗性があります.
- AVA耐性の基礎となるメカニズムは完全に理解されず,治療効果を阻害しています.
- 乳がん1型感受性タンパク質 (BRCA1) 関連RING領域1 (BARD1) の機能は,この文脈では未研究である.
研究 の 目的:
- 血管内膜成長因子抗体 (AVA) に対する感受性を調節するBARD1の役割を調査する.
- AVA抵抗を克服するための表遺伝的戦略を探求する.
- BARD1を標的とした新しい治療法を開発し,がん治療の改善を目指す.
主な方法:
- 血管新生におけるBARD1の役割を評価するために,DNAメチル化 (全局的および標的型) を用いた表遺伝子調節.
- AVA耐性を克服するためにアザチチジンによる順次治療のインビボ評価.
- 精密なエピジェネティック再活性化のために,BARD1を標的とするsgRNAを持つ,リポソーマのCRISPRで無効化されたCas9 (dCas9) - TET1システムの開発.
主要な成果:
- BARD1は血管新生の重要なレギュラーとして特定され,AVAの感受性に影響を与えます.
- アザシチジン治療は,AVA抵抗を克服する効果を in vivoで示した.
- dCas9- TET1システムは,BARD1プロモーターのCpG特異的な脱メチル化に成功し,その発現を回復し,AVA応答を改善しました.
- 卵巣がんのモデルでは,dCas9- TET1またはsiRNAによるBARD1の復元により,AVAと併用した腫瘍の成長が著しく減少しました.
結論:
- BARD1は腫瘍の血管新生とAVA感受性において,これまで認識されていない重要な役割を果たしています.
- dCas9-TET1システムが示した遺伝子特有の表遺伝的ターゲティングは,AVA抵抗を克服する有望な戦略を提供します.
- BARD1の発現を回復することは,抗血管新生がん治療の強化のための潜在的な治療方法である.
関連する概念動画
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
TGF - β Signaling Pathway
7.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K


